Vimarsana
Biggest News Aggregation in the World

Page 7 - Beckley Psytech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beckley Psytech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beckley Psytech Today - Breaking & Trending Today

Atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics - Vimarsana News

Atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

Strategic investment in Beckley Psytech reinforces atai’s position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo...

atai Life Sciences expands its pipeline with $50M investment in Beckley Psytech - Vimarsana News

atai Life Sciences expands its pipeline with $50M investment in Beckley Psytech

Psychedelic drug development firm atai Life Sciences (NASDAQ:ATAI) is investing $50 million in UK-based Beckley Psytech as part of a collaboration that...

Cedar Clinical Research Selected as Clinical Research Site for Beckley Psytech's Phase 2B Study - Vimarsana News

Cedar Clinical Research Selected as Clinical Research Site for Beckley Psytech's Phase 2B Study

Numinus Wellness Inc. announce that its research site, Cedar Clinical Research , has been chosen as one of multiple sites for Beckley Psytech's cutting-edge Phase 2b clinical trial for Treatment...

Cedar Clinical Research selected as clinical research site for Beckley Psytech's Phase 2b Study - Vimarsana News

Cedar Clinical Research selected as clinical research site for Beckley Psytech's Phase 2b Study

/PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative...

First Patient Dosed in Beckley Psytech's International Phase IIb Study of BPL-003, a Novel Synthetic Intranasal Formulation of 5-MeO-DMT, for Treatment Resistant Depression (TRD) | Region - Vimarsana News

First Patient Dosed in Beckley Psytech's International Phase IIb Study of BPL-003, a Novel Synthetic Intranasal Formulation of 5-MeO-DMT, for Treatment Resistant Depression (TRD) | Region

OXFORD, England--(BUSINESS WIRE)--Oct 24, 2023--